Where DICE Therapeutics Stands With Analysts
Within the last quarter, DICE Therapeutics (NASDAQ:DICE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
DICE Therapeutics Q3 EPS $(0.55) Up From $(2.15) YoY
DICE Therapeutics (NASDAQ:DICE) reported quarterly losses of $(0.55) per share. This is a 74.42 percent increase over losses of $(2.15) per share from the same period last year.
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday
Gainers
FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesday.
Nasdaq Drops 150 Points; AZZ Shares Plummet
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 150 points on Tuesday.
SVB Leerink Maintains Outperform on DICE Therapeutics, Raises Price Target to $77
SVB Leerink analyst Thomas Smith maintains DICE Therapeutics (NASDAQ:DICE) with a Outperform and raises the price target from $46 to $77.
HC Wainwright & Co. Maintains Buy on DICE Therapeutics, Raises Price Target to $60
HC Wainwright & Co. analyst Emily Bodnar maintains DICE Therapeutics (NASDAQ:DICE) with a Buy and raises the price target from $40 to $60.
Why ForgeRock Shares Are Trading Higher By Over 49%, Here Are 50 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
FedNat Holding Company (NASDAQ: FNHC) shares jumped 140% to $0.3939.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers
DICE Therapeutics (NASDAQ:DICE) stock moved upwards by 83.4% to $45.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.7 billion.